Analysis Of Income And Expense [Abstract]

GenSight Biologics S.A. - Filing #832858

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue	—	1,267,000 EUR	—	—	—	—	—	—	2,582,000 EUR	—
Material income and expense [abstract]
Research and development expense	—	19,360,000 EUR	—	—	—	—	—	—	19,343,000 EUR	—
Finance income (cost)	—	3,475,000 EUR	—	—	—	—	—	—	215,000 EUR	—
Selling, general and administrative expense [abstract]
General and administrative expense	—	5,352,000 EUR	—	—	—	—	—	—	5,361,000 EUR	—
Revenue and other operating income	—	2,963,000 EUR	—	—	—	—	—	—	4,865,000 EUR	—
Operating expense	—	32,659,000 EUR	—	—	—	—	—	—	32,700,000 EUR	—
Sales and marketing expense	—	7,947,000 EUR	—	—	—	—	—	—	7,996,000 EUR	—
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	— EUR	103,000 EUR	— EUR	— EUR	103,000 EUR	174,000 EUR	— EUR	— EUR	174,000 EUR	— EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	0 EUR	26,111,000 EUR	26,220,000 EUR	0 EUR	109,000 EUR	124,000 EUR	0 EUR	27,625,000 EUR	27,748,000 EUR	0 EUR